We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Early-Phase Clinical Trials Program

HOSPITAL
University Hospitals Seidman Cancer Center

KEY CONTACTS
Afshin Dowlati, MD, Director, Center for Cancer Drug Development 216-844-1228, Afshin.Dowlati@UHhospitals.org

APPOINTMENT LINE
Please call Erica Gentile, New Patient Intake Coordinator, at 216-286-2292.
For hospital transfers, please call 216-844-1111.

Conditions Treated

  • Any recurrent or refractory cancers
  • Any cancer where standard therapy can be improved

Therapies

  • New targeted therapies
  • Immunotherapy
  • Cell therapies
  • Cancer vaccines
  • Proton beam therapy

Distinguishing Features

  • Part of NCI-designated Case Comprehensive Cancer Center
  • Dedicated team with specialized expertise in early-phase clinical trials
  • Genomic evaluation for optimal selection of studies
  • Specialized Adolescent and Young Adult (AYA) cancer program
  • Access to new drugs in NCI portfolio as members of NCI Experimental Therapeutic Clinical Trials Network
  • Extensive portfolio of Phase I and Phase II treatment studies